PPT-SMV + DCV + SOF Open label

18 years Chronic HCV infection Genotype 1 or 4 HCV RNA gt 10 000 IUml Treatmentnaïve or pretreated w ith PEGIFN RBV Cirrhosis gt 145 kPa on FibroScan Portal hypertension or liver . 1 716 60 382 16 73 18 18 20 25 D4110 98 91 58 10 45 14 29 D4111 47 279 241 170 22 92 12 32 D4112 315 851 213 428 121 276 37 80 D4117 947 2358 1105 1357 647 823 95 493 86 86 D4124 283 494 152 358 173 499 296 3471 35 35 D4125 381 754 74 304 17 140 83 O 1 716 60 382 16 73 18 18 20 25 D4110 98 91 58 10 45 14 29 D4111 47 279 241 170 22 92 12 32 D4112 315 851 213 428 121 276 37 80 D4117 947 2358 1105 1357 647 823 95 493 86 86 D4124 283 494 152 358 173 499 296 3471 35 35 D4125 381 754 74 304 17 140 83 O SMV 24W + PEG-IFN + RBV 24-48W **. Randomisation *. 1:1. Open-label. 20-70 years, Japanese. Chronic HCV infection. Genotype 1. HCV RNA ≥ 100 000 IU. /ml. IFN-based pre-treated, . non-responders. No prior DAA therapy. N = 69. >. 18 years. Failure to SOF/VEL . or SOF/VEL + VOX . (LEPTON study). Any genotype. Compensated cirrhosis allowed. No HBV or HIV co-infection. Open-label. SOF/VEL: 400/100 mg FDC QD ; RBV: weight based in twice daily dose . in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 : 2 : 1*. Open-label. * . Randomisation. was stratified on genotype (1a or 1b) in both cohorts, . IL28B . in cohort 1 and treatment history (naïve or non-responder) in cohort . in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. 400/100/100 mg QD. N = 263. N = 152. W12. Placebo. >. 18 years. Chronic HCV infection. Genotype 1, 2, 3, 4, 5 or 6. NS5A inhibitor-experienced . for ≥ 4 weeks (exclusion if . discontinued due to an adverse. Design. Objective. SVR. 12. (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotyp. e 1 . treated for 12. . weeks. DCV +. SOF 400 mg QD. DCV + . SOF 400 mg QD. Randomisation. *. 2 : 1. Open-label. Design. Objective. SVR. 12. (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotyp. e 1 . treated for 12. . weeks. DCV +. SOF 400 mg QD. DCV + . SOF 400 mg QD. Randomisation. *. 2 : 1. Open-label. Interim Analysis of a French Multicenter Compassionate Use Program. Christophe Hézode,. 1. Victor De Ledinghen,. 2. Helene Fontaine,. 3. Fabien Zoulim,. 4. Pascal Lebray,. 5. Nathalie Boyer,. 6. Arie Gurfinkel (SEI/CMU). based on material by Prof. Clarke and others. Brief Review. 2/18/2005. 3. Symbolic Model . Verifier (SMV). Ken McMillan, . Symbolic Model Checking: An Approach to the State Explosion Problem. Int J Anat Var Vol 12 No 1 March 201924 Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia-PA 19131, USACorrespondence: Dr. Mei Xu, Department of Bio-Medica kindly visit us at www.nexancourse.com. Prepare your certification exams with real time Certification Questions & Answers verified by experienced professionals! We make your certification journey easier as we provide you learning materials to help you to pass your exams from the first try.